About Us
Our Technology
Virtus' first disease target is PKAN (Pantothenate Kinase-Associated Neurodegeneration). We use biochemical, cell biological, structural, genomic, transcriptomic, metabolomic and proteomic data to guide our strategy to develop the most effective therapy for treatment of this genetic disorder.
Subscribe
Sign up to hear from us.
Leadership
Founder
Board Member
Board Member
Choukri Ben Mamoun, PhD
Professor of Medicine, Microbial Pathogenesis and Pathology.
Yale University
Reviews
Contact Us
Please send us a message or call us for an appointment.
Virtus Therapeutics
Hours
Monday - Friday: 8:00am - 5:00pm
Saturday - Sunday: Closed
Copyright © 2023 Virtus Therapeutics - All Rights Reserved.
Powered by GoDaddy
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.